Treatment of Dyspareunia with Botulinum Neurotoxin Type A: Clinical Improvement and Influence of Patients’ Characteristics
Open Access
- 20 August 2021
- journal article
- research article
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 18 (16) , 8783
Abstract
The treatment of chronic pelvic pain (CPP) with botulinum neurotoxin type A (BoNT/A) has increased lately, but more studies assessing its effect are needed. This study aimed to evaluate the evolution of patients after BoNT/A infiltration and identify potential responders to treatment. Twenty-four women with CPP associated with dyspareunia were treated with 90 units of BoNT/A injected into their pelvic floor muscle (PFM). Clinical status and PFM activity were monitored in a previous visit (PV) and 12 and 24 weeks after the infiltration (W12, W24) by validated clinical questionnaires and surface electromyography (sEMG). The influence of patients’ characteristics on the reduction in pain at W12 and W24 was also assessed. After treatment, pain scores and the impact of symptoms on quality of life dropped significantly, sexual function improved and sEMG signal amplitude decreased on both sides of the PFM with no adverse events. Headaches and bilateral pelvic pain were risk factors for a smaller pain improvement at W24, while lower back pain was a protective factor. Apart from reporting a significant clinical improvement of patients with CPP associated with dyspareunia after BoNT/A infiltration, this study shows that clinical characteristics should be analyzed in detail to identify potential responders to treatment.Keywords
Funding Information
- Universitat Politècnica de València (Programa de Ayudas de Investigación y Desarrollo (PAID-01-20), ISCIII, MCIU, VLC Campus in Convocatoria Ayudas: UPV-La Fe (INBIO): 2016 SPEHG (ID:C18), 2019 sEMG_BONTAv (ID:C06))
- Merz Pharmaceuticals (Private funds)
This publication has 28 references indexed in Scilit:
- Migraine and Central Sensitization: Clinical Features, Main Comorbidities and Therapeutic PerspectivesCurrent Rheumatology Reviews, 2016
- The Botulinum Toxin as a Therapeutic Agent: Molecular Structure and Mechanism of Action in Motor and Sensory SystemsSeminars in Neurology, 2016
- Botulinum Toxin A Injections Into Pelvic Floor Muscles Under Electromyographic Guidance for Women With Refractory High-Tone Pelvic Floor DysfunctionUrogynecology, 2015
- Botulinum Toxin for Neuropathic Pain: A Review of the LiteratureToxins, 2015
- Evaluation of Third-Degree and Fourth-Degree Laceration Rates as Quality IndicatorsObstetrics & Gynecology, 2015
- Non-surgical interventions for the management of chronic pelvic painCochrane Database of Systematic Reviews, 2014
- Botulinum Toxin Type A (BOTOX) for Refractory Myofascial Pelvic PainUrogynecology, 2013
- Botulinum Neurotoxin Type A Injections for Vaginismus Secondary to Vulvar Vestibulitis SyndromeObstetrics & Gynecology, 2009
- Women's Sexual Pain and its ManagementThe Journal of Sexual Medicine, 2005
- The extraction of neural strategies from the surface EMGJournal of Applied Physiology, 2004